{"id":"https://genegraph.clinicalgenome.org/r/c3dd501d-a057-4428-911e-018a5645a270v2.0","type":"EvidenceStrengthAssertion","dc:description":"F9 encodes coagulation factor FIX that forms the tenase complex with FVII to activate FX in the coagulation cascade. F9 was first reported in relation to X-linked thrombophilia due to factor 9 defect in 2009 (Simioni et al, PMID: 19846852). Evidence supporting this gene-disease relationship includes case-level data only. Just two, missense variants have been reported in relation to thrombophilia. Two siblings from 1 publication have been reported with the hemizygous missense variant, Arg384Leu (PMID: 19846852) and and additional patient with Arg384Gln (PMID: 32079698). The mechanism is reported to be gain of function. While a few other polymorphisms, including F9 Malmo have been reported in association with risk of deep vein thrombosis, the biological mechanism for the association is not known. These variants have not been included in this curation. \n  \nIn summary, the level of evidence to support the gene-disease relationship of F9 and X-linked thrombophilia due to factor 9 defect is limited. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged.\n\nThis gene-disease pair was originally evaluated by the HT GCEP on June 24, 2020. It was reevaluated on 10/24/2023. As a result of this reevaluation one additional patient was identified (PMID: 32079698) however the classification remained Limited (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/c3dd501d-a057-4428-911e-018a5645a270","GCISnapshot":"https://genegraph.clinicalgenome.org/r/9b3a7f2c-a07a-4a10-b1f7-78642ebdaa5d","calculatedEvidenceStrength":"Limited","changes":[{"id":"cg:summaryChange"},{"id":"cg:sopChange"},{"id":"cg:newEvidence"},{"id":"cg:otherTextChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/9b3a7f2c-a07a-4a10-b1f7-78642ebdaa5d_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10028","date":"2023-11-06T14:20:57.439Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/9b3a7f2c-a07a-4a10-b1f7-78642ebdaa5d_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10028","date":"2023-11-06T17:00:00.000Z","role":"Approver"}],"curationReasons":["RecurationTiming","RecurationNewEvidence"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9b3a7f2c-a07a-4a10-b1f7-78642ebdaa5d_experimental_evidence_line","type":"EvidenceLine","specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/9b3a7f2c-a07a-4a10-b1f7-78642ebdaa5d_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b79a889f-d534-4b0d-805a-7e4c2882a4c4","type":"EvidenceLine","dc:description":"FIX-deficient plasma was reconstituted with FIX isolated from proband's plasma and with FIX isolated from control plasma, resulting in FIX clotting activity of 834% and 100% of normal, respectively.\n\nGene therapy with recombinant viral vectors carrying this variant are reported to effectively increase FIX levels in dogs, mice, and humans with Hemophilia B (PMID: 23197580, 22919027, 29211678).\n\nThe variant is not reported in gnomAD and is awarded increased points owing to its correlation to increased FIX levels, as seen in gene therapy experiments.\n","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b79a889f-d534-4b0d-805a-7e4c2882a4c4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19846852","allele":{"id":"https://genegraph.clinicalgenome.org/r/5f7f3469-07ce-465b-906d-57666e4243b0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000133.4(F9):c.1151G>T (p.Arg384Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/10668"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/b79a889f-d534-4b0d-805a-7e4c2882a4c4_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"From PMID: 33656538 --The substitution was introduced into hFIX-WT cDNA and transfected into  HEK293 cells. This mutation resulted in increased specific activity >15 fold.\n\nSimilar results were observed with cFIX cDNA as well as 3 different human cell lines (HepG2, Huh7, and SK-Hep).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d791d34a-1bf8-430b-aba2-3de6d4c4f825","type":"EvidenceLine","dc:description":"A coagulation function assay with the patientâ€™s plasma also had  increased FIX activity (FIX:C around 143.1% of normal).\n\nWhen the FIX with the p.R338Q modification was expressed in vivo after being transferred with self-complementary adeno-associated virus (scAAV) vectors, the deficiency of FIX in a mouse model of hemophilia B was restored, and the bleeding phenotype was significantly ameliorated.\n\nThe variant is not reported in gnomAD and is awarded increased points owing to its correlation to increased FIX levels, as seen in gene therapy experiments.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d791d34a-1bf8-430b-aba2-3de6d4c4f825_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32079698","allele":{"id":"https://genegraph.clinicalgenome.org/r/fc0c1f8d-479e-46ea-8f78-3c501f184813","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000133.4(F9):c.1151G>A (p.Arg384Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414446196"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/d791d34a-1bf8-430b-aba2-3de6d4c4f825_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The F9 cDNA containing the p.R338Q mutation was inserted into the mammalian expression vector pCDNA3.1 and transfected into HEK293T cells. A coagulation function assay with the recombinant FIX showed that the mutation had increased FIX activity by approximately 5- fold.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":2}],"evidenceStrength":"Limited","sequence":7173,"specifiedBy":"GeneValidityCriteria9","strengthScore":2,"subject":{"id":"https://genegraph.clinicalgenome.org/r/IT2X_53pK6c","type":"GeneValidityProposition","disease":"obo:MONDO_0010432","gene":"hgnc:3551","modeOfInheritance":"obo:HP_0001417"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_9b3a7f2c-a07a-4a10-b1f7-78642ebdaa5d-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}